Sherman Kenneth E
Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Rev Gastroenterol Disord. 2004;4 Suppl 1:S48-54.
Liver disease has emerged as a major cause of morbidity and mortality in patients infected with the human immunodeficiency virus. Hepatic injury is highly associated with hepatitis C virus (HCV) infection, though hepatitis B virus and drug-induced hepatotoxicity are also important cofactors. HCV coinfection is linked to increased hepatic fibrosis progression, leading to development of cirrhosis and liver failure earlier than in HCV monoinfected patients. Initiation of highly active antiretroviral treatment regimens may paradoxically increase HCV loads. Some data suggest that HCV coinfection may hasten progression of AIDS, but this remains controversial. Three major randomized clinical trials demonstrate improved efficacy of peginterferon with ribavirin for treatment of HCV in coinfected subjects compared to those with HCV alone. However, response rates are lower than those observed in patients with HCV monoinfection. Sustained virologic response rates of 27% to 40% are reported.
肝脏疾病已成为感染人类免疫缺陷病毒患者发病和死亡的主要原因。肝损伤与丙型肝炎病毒(HCV)感染高度相关,尽管乙型肝炎病毒和药物性肝毒性也是重要的辅助因素。HCV合并感染与肝纤维化进展加快有关,导致肝硬化和肝衰竭的发生比单纯HCV感染患者更早。启动高效抗逆转录病毒治疗方案可能会反常地增加HCV载量。一些数据表明,HCV合并感染可能会加速艾滋病的进展,但这仍存在争议。三项主要的随机临床试验表明,与单纯HCV感染患者相比,聚乙二醇干扰素联合利巴韦林治疗合并感染患者的HCV疗效有所提高。然而,应答率低于单纯HCV感染患者。据报道,持续病毒学应答率为27%至40%。